![Anne Prener](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anne Prener
Director/Board Member at
XSPRAY PHARMA AB
Net worth: - $ as of 31/05/2026
Profile
Anne Prener is currently Director at Xspray Pharma AB since 2025, Director at Cellinta Ltd. since 2020, and Director at Keros Therapeutics, Inc. starting in 2026.
Former roles include Chief Executive Officer at Syncona Ltd., Chief Executive Officer & Director at Spur Therapeutics Ltd. from 2017 to 2019, President, Chief Executive Officer & Director at Imbria Pharmaceuticals, Inc. from 2020 to 2024, Chief Executive Officer at Gyroscope Therapeutics Ltd. from 2016 to 2017, Independent Director at Rubius Therapeutics, Inc. from 2019 to 2022, Director at Renovacor Holdings, Inc., Independent Director at Kaleido Biosciences, Inc. from 2020 to 2022, Independent Director at Damora Therapeutics, Inc. from 2021 to 2025, SVP-Hemophilia Research & Development Portfolio at Novo Nordisk A from 2011 to 2012, Vice President-Clinical Research Hematology at Baxalta, Inc. from 2014 to 2016, Council/Board member at Novo Nordisk (Private Equity) from 2010 to 2014, and Venture Partner at SV Health Investors LLP from 2020 to 2024.
Education includes graduate and doctorate degrees from the University of Copenhagen, both conferred in 1984.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/06/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Anne Prener active positions
| Companies | Position | Start |
|---|---|---|
| XSPRAY PHARMA AB | Director/Board Member | 01/01/2025 |
| KEROS THERAPEUTICS, INC. | Director/Board Member | 01/07/2026 |
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Functions as an alternative investment manager for healthcare industry | Director/Board Member | 27/03/2020 |
Former positions of Anne Prener
| Companies | Position | End |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Director/Board Member | 10/11/2025 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors invests in companies located across the Globe. The firm focuses on biotechnology, pharmaceuticals, medical devices & instruments and healthcare services sectors. It provides financing for seed, early, growth stage and buyout capital requirements. | Private Equity Investor | 01/10/2024 |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Chief Executive Officer | 01/09/2024 |
| RUBIUS THERAPEUTICS | Director/Board Member | 12/07/2022 |
| KALEIDO BIOSCIENCES, INC. | Director/Board Member | 01/04/2022 |
Training of Anne Prener
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
70
1st degree connections
16
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors invests in companies located across the Globe. The firm focuses on biotechnology, pharmaceuticals, medical devices & instruments and healthcare services sectors. It provides financing for seed, early, growth stage and buyout capital requirements. | Finance |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk (Private Equity)
 Novo Nordisk (Private Equity) Investment ManagersFinance NNBF invests equity into promising young companies in the health science industry, with a focus on Europe and North America. Their investment strategy focuses on start-ups and later stage biotech firms with a high level of relevance for Novo Nordisk's business model. NNBF focuses on Inflammation, Diabetes, Obesity, Haemostasis, Protein Delivery Systems and Devices, along with Enabling Technologies supporting relevant therapeutic areas. | Finance |
Xspray Pharma AB
 Xspray Pharma AB Pharmaceuticals: MajorHealth Technology Develops and produces particulate materials for the pharmaceutical industry | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
Kaleido Biosciences, Inc.
 Kaleido Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company which develops therapeutic products to systematically shape the micro biome | Health Technology |
Keros Therapeutics, Inc.
 Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Develops transformative gene therapy | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Functions as an alternative investment manager for healthcare industry | Finance |
- Stock Market
- Insiders
- Anne Prener
Choose MarketScreener 
